Sonoma Biotherapeutics

📍 South San Francisco, United States👥 125 employees💰 Last funded 2020
Biotechnology Research🌐 sonomabio.com
Website LinkedIn
Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Sonoma Biotherapeutics?
Sonoma Biotherapeutics has 2 investors on record on gritt.io.
When did Sonoma Biotherapeutics last raise funding?
The most recent investment in Sonoma Biotherapeutics recorded on gritt.io was in 2020.
What industry is Sonoma Biotherapeutics in?
Sonoma Biotherapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Sonoma Biotherapeutics based?
Sonoma Biotherapeutics is headquartered in South San Francisco, United States.